2022
DOI: 10.1001/jamanetworkopen.2022.10743
|View full text |Cite
|
Sign up to set email alerts
|

Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State–wide Psychiatric Hospital System

Abstract: Key Points Question Is psychotropic medication use associated with differences in the risk of COVID-19 infection among adults with serious mental illness? Findings In this cohort study of 1958 inpatients with serious mental illness in a statewide psychiatric hospital system, the use of second-generation antipsychotic medications was associated with a decreased risk of COVID-19 infection; the largest association was observed with the use of paliperidone. Val… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
20
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(21 citation statements)
references
References 40 publications
(74 reference statements)
1
20
0
Order By: Relevance
“…A recent study further suggested antipsychotic drugs might be inhibiting viral replication (Fred et al, 2022). A clinical trial found that second-generation antipsychotics was associated with decreased risk of COVID-19 infection in patients in the New York State–wide psychiatric hospital system (Nemani et al, 2022). Interestingly, though the decrease in risk of infection with CPZ (a first-generation antipsychotic) was not quite statistically significant, none of the 47 COVID-19 infected patients taking CPZ died of COVID-19 related causes.…”
Section: Discussionmentioning
confidence: 99%
“…A recent study further suggested antipsychotic drugs might be inhibiting viral replication (Fred et al, 2022). A clinical trial found that second-generation antipsychotics was associated with decreased risk of COVID-19 infection in patients in the New York State–wide psychiatric hospital system (Nemani et al, 2022). Interestingly, though the decrease in risk of infection with CPZ (a first-generation antipsychotic) was not quite statistically significant, none of the 47 COVID-19 infected patients taking CPZ died of COVID-19 related causes.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, the latest studies also indicate the adverse events of psychotropic medications influencing the weakening of the immune system or the risk of developing dementia. Nemani et al [ 87 ] demonstrated that there is a link between the use of psychotropic medications and the increased risk of COVID-19 infection [ 87 ]. Concurrently, pre-COVID-19 psychotropic medication exposure was associated with a greater 1-year incidence of dementia after COVID-19 infection [ 88 ].…”
Section: The Influence Of the Covid-19 Pandemic On Mental Healthmentioning
confidence: 99%
“…Some confirmation of their observations could come from an analysis of 2,087 mental health patients hospitalised in New York City hospitals in 2020. It showed that the use of atypical antipsychotics reduced the risk of COVID-19 infection, and paliperidone stood out in this regard (Nemani et al, 2022). Despite these encouraging insights, it seems that further exploration of the issue is needed.…”
Section: Atypical Antipsychoticsmentioning
confidence: 99%
“…Clinical experiences with VPA are inconclusive. Regarding the effect on the incidence of COVID-19 infection, the aforementioned New York study assessed valproate as increasing the risk of COVID-19 infection (Nemani et al, 2022). In contrast, Spanish researchers report a significantly lower percentage of morbidity and hospitalisation due to COVID-19 in patients using VPA (Moreno-Perez et al, 2022).…”
Section: Valproatementioning
confidence: 99%